

Food and Drug Administration Center for Biologics Evaluation and Reseated 1401 Rockville Pike Rockville MD 20852-1448

AUG 2 0 2001

Carolyn D. Jones AdvaMed 1200 G Street NW Suite 400 Washington, DC 20005-3814

Docket No. 01D-0171

Dear Ms. Jones:

This letter is to provide you an update regarding your proposed guidance document "Guidance for Industry and CBER Reviewers: Guidance for the Content of Premarket Notifications for Automated Blood Cell Separators Used in the Collection of Peripheral Blood Hematopoietic Stem Cells," submitted by the Advanced Medical Technology Association's Blood Processing Working Group and filed with the Dockets Management Branch on March 29, 2001. You requested that FDA review the proposed guidance for consideration as an FDA approved guidance. Thank you for your interest in pursuing guidance in this area.

The Center for Biologics Evaluation and Research (CBER) intends to review your submission more fully. We may decide to make revisions to it and announce it in the Federal Register as a draft guidance document for public comment in the future. Until such a determination is made, we cannot establish a proposed date of issuance. If you have any questions, please contact Stephen Ripley, Regulations and Policy Staff at 301-827-6345.

Sincerely yours,

Diane Maloney

Associate Director for Policy

01D-017/

LETI